Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression.

ABSTRACT:

Background

Medulloblastoma (MB) is the most common pediatric brain tumor. Although standard-of-care treatment generally results in good prognosis, many patients exhibit treatment-associated lifelong disabilities. This outcome could be improved by employing therapies targeting the molecular drivers of this cancer. Attempts to do so in the SONIC HEDGEHOG MB subgroup (SHH-MB) have largely focused on the SHH pathway's principal activator, smoothened (SMO). While inhibitors targeting SMO have shown clinical efficacy, recurrence and resistance are frequently noted, likely resulting from mutations in or downstream of SMO. Therefore, identification of novel SHH regulators that act on the pathway's terminal effectors could be used to overcome or prevent such recurrence. We hypothesized that

SUBMITTER: Wynn DT 

PROVIDER: S-EPMC9586216 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature